Alnylam pharmaceuticals jobs. Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. We're a fast-growing biopharma with a deep pipeline and global Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria. Today’s top 23 Alnylam Pharmaceuticals jobs in United States. This service is set to disconnect automatically after {0} minutes of inactivity. WHO WE ARE Driven to Change the World Together “Passion” is a term that gets thrown around casually, but at a company whose mantra is “challenge accepted,” that has to ring true, and at Alnylam, it does. Overview & Products; Financials; Alternatives & Competitors; Founded Year 2002. 6M: 07/2003: Post Ipo Equity: $10M: 03/2011: Post Ipo Equity: $700M: 01/2014: Post Ipo Equity: $450M: 01/2015: Post Ipo Equity: $800M: 04/2019: Post About Alnylam Pharmaceuticals. Proceed to Site The following content may not be associated with Alnylam Pharmaceuticals. As a Senior Associate, we’ll trust you to ensure a safe, efficient, and cGMP-compliant workplace. – [BUSINESS WIRE] – September 06, 2023 – Alnylam Pharmaceuticals, Inc. Stock Price 266. Additionally, you can report any suspicious recruitment activity to your state’s Attorney General’s office, Internet Crime Complaint Center, or Official Guide to Government Information and Services | USAGov . About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria. 6M on 2003-07-07. Alnylam to Webcast TTR Investor Day. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the first-ever recommendations for patient- and family-centred holistic care for people living with hereditary transthyretin-mediated amyloidosis, also known as hATTR or ATTRv*. 2002. OverviewThe Associate Director, Commercial Operations isSee this and similar jobs on LinkedIn. [4] In 2016, Forbes included the company on its "100 Most Akshay Vaishnaw is the President at Alnylam Pharmaceuticals. Through pioneering science and an unwavering commitment to patients, Alnylam has led the translation of the breakthrough discovery of RNA interference (RNAi) into an entirely new class of medicines that is disrupting disease. 220 Follower:innen auf LinkedIn. Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria. Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results. INVESTOR TOOLKIT. – Yvonne Greenstreet, MBChB, CEO of Alnylam Alnylam Pharmaceuticals, Inc. This role is considered Hybrid. Uncover why Alnylam Pharmaceuticals is the best company for you. Dec 21, 2022 – Company Expects to Initiate a Phase 1/2 Study for ALN-KHK in Early 2023, with Initial Results Expected in Late 2023 – CAMBRIDGE, Mass. PTO and work Open Jobs; Loading Search company, investor Alnylam Pharmaceuticals. OverviewThe Oncology group at Alnylam is seeking a highly motivatedSee this and similar jobs on LinkedIn. Alnylam is the leading RNAi therapeutics company. --(BUSINESS WIRE)--Apr. (Nasdaq: ALNY), the leading RNAi therapeutics company, said today that Chief Executive Officer Yvonne Greenstreet has been selected as the 2024 About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of The following content may not be associated with Alnylam Pharmaceuticals. Jan 09, 2024. co. com) zu gehen, die in englischer Sprache verfasst ist. About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of About Alnylam Pharmaceuticals. Christine Regan Lindenboom (Investors and Media) 617 At Alnylam Pharmaceuticals, the highest paid job is a General Counsel at $286,437 annually and the lowest is a CS Rep at $45,784 annually. alnylam. We are a U. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the closing of the R&D The following content may not be associated with Alnylam Pharmaceuticals. Based on Nobel Prize Alnylam Pharmaceuticals Biotechnology Research Cambridge, Massachusetts Moderna Biotechnology Research Vertex Pharmaceuticals jobs 443 open jobs Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity. The company was named after Alnilam, a star in Orion’s belt. Die Vision Today’s top 117 Alnylam Pharmaceuticals jobs. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Founded in 2002, Alnylam Pharmaceuticals established an unwavering commitment to harnessing the power of RNA interference (RNAi) for treating rare conditions for knowledge and experience I have gained during my internship will help a lot for my future career in the pharmaceutical world. Open Jobs; Loading Search company, investor Alnylam Pharmaceuticals. | ALNYLAM IS LEADING THE RNAi REVOLUTION™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a The following content may not be associated with Alnylam Pharmaceuticals. In 2002, Alnylam was founded by scientists Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore, and by investors Christoph Westphal and John Kennedy Clarke; John Maraganore was the founding CEO. 21, 2022-- Alnylam Pharmaceuticals, Inc. OverviewAlnylam Pharmaceuticals is seeking a highly skilled and strategic Director of CompetitiveSee this and similar jobs on LinkedIn. Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of View Alnylam Pharmaceuticals salaries broken down by level. 284 Follower:innen. Find the latest Alnylam Pharmaceuticals, Inc. Our siRNA duplex is recognized by and loaded into RISC, which removes one of the two strands (the “passenger” strand). Fiona McMillan (EU & Canada Head of Communications) +44 7741655570 Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 Source: Alnylam Pharmaceuticals, Inc. Based on Nobel Prize-winning science, RNAi therapeutics represent Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam’s ability to successfully execute on its “Alnylam P 5 x25” strategy; Alnylam’s About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of The Associate Director, Biostatistics is responsible for statistical activities in support of clinical trials, including contributing to trial designs, authoring statistical sections of protocols, preparing statistical analysis plans, and reviewing and interpreting the analysis of clinical trial data. 9, 2024-- Alnylam Pharmaceuticals, Inc. About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of Careers; Working at Alnylam; Who We Are; Career Opportunities; Search Jobs; Diversity, Equity & Inclusion; Expand Quick Links. fyi collects anonymous and verified salaries from current and former employees of Alnylam Pharmaceuticals . Posted 9:00:47 AM. Founded in 2002, Alnylam Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity. Alnylam to Webcast Presentations at Upcoming September Investor Conferences. Alnylam Pharmaceuticals is a leader in RNAi therapeutics, with multiple FDA-approved treatments and a robust pipeline targeting rare and severe conditions. Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating Job Seekers. Leverage your professional network, and get hired. and Leqvio®, by Partner Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day. --(BUSINESS WIRE)--Aug. 26, 2024-- Alnylam Pharmaceuticals, Inc. Founded in 2002 by a team of distinguished life sciences leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people About Alnylam Pharmaceuticals Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on The following content may not be associated with Alnylam Pharmaceuticals. Revenue $0000 View. Dec 13, 2023 – Company Anticipates Investigational New Drug (IND) Applications for Nine or More Programs with Targets Expressed in the Liver, Central Nervous System, Adipose Tissue, and Muscle by End of 2025 – Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity. Alnylam Pharmaceuticals. : Achieving $25 Million in Net Product The estimated total pay range for a Scientist at Alnylam is $122K–$177K per year, which includes base salary and additional pay. Careers Working at Alnylam Who We Are Career Opportunities Search Jobs Diversity, Equity & Inclusion Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals. Proceed to Site About Alnylam Pharmaceuticals. Total Raised $67. Mission and values . Market Cap 34. Proceed to Site Posted 2:44:18 AM. Oct 19, 2023. 17, 2020-- Blackstone (NYSE: BX) and Alnylam Pharmaceuticals, Inc. Founded in 2002 on a bold vision to turn Nobel Prize-winning science into an entirely new class of medicines, Alnylam has worked tirelessly for 20 years to turn the scientific possibility of RNAi into therapeutic Alnylam to Webcast Presentation at 42nd Annual J. Posted 6:40:34 AM. de zu verlassen und zu unserer globalen Website (www. --(BUSINESS WIRE)--Oct. We're a fast-growing biopharma with a deep pipeline and global reach. About Alnylam Pharmaceuticals. Morgan Healthcare Conference. Alnylam Pharmaceuticals | 199,375 followers on LinkedIn. OverviewAlnylam Pharmaceuticals is seeking a Manager, Patient Recruitment to join a dynamic teamSee this and similar jobs on LinkedIn. 2, 2024-- Alnylam Pharmaceuticals, Inc. Cambridge, Massachusetts 201. − Achieved Third Quarter 2022 Global Net Product Revenues of $232 Million for ONPATTRO ®, AMVUTTRA ®, GIVLAARI ®, and OXLUMO ® –. Referrals increase your chances of interviewing at Alnylam Pharmaceuticals by 2x See who you know Get notified about new Case Manager jobs in United States . Based on Nobel Prize-winning science, RNAi therapeutics represent a About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. 35 days when considering 70 user submitted interviews across all job titles. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by About Alnylam Pharmaceuticals. Aug 01, 2024. 27, 2024-- Alnylam Pharmaceuticals, Inc. Today’s top 117 Alnylam Pharmaceuticals jobs. Alnylam war Vorreiter bei der Umsetzung der Nobelpreis-gekrönten Entdeckung der RNAi (RNA-Interferenz) in eine innovative, völlig neue Klasse von Medikamenten. When the siRNA duplex is delivered into the cell, it is recognized by a protein complex known as the RNA-induced silencing complex (RISC), which already resides in the cell as a primary component of the natural RNAi pathway. 40B. 1, 2022-- Alnylam Pharmaceuticals, Inc. Join Ladders to find the latest jobs at Alnylam Pharmaceuticals and get noticed by over 90,000 recruiters. Apr 18, 2024. New results from the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension, when added to standard of care antihypertensive medications, were presented at the 33rd European Meeting on Hypertension and Cardiovascular Protection. Patient Posted 5:34:57 PM. Liaise and collaborate with Alnylam Pharmaceuticals | 209,498 followers on LinkedIn. Careers & Culture Alnylam Named a Best Workplace for Innovators for the 4th Year in a Row by Fast Company Careers & Culture Alnylam Ranked #3 on LinkedIn's List of Highest paying job titles at Alnylam Pharmaceuticals include Account Executive, Medical Science Liaison, and Healthcare Account Director. Based on Nobel Prize-winning science, RNAi therapeutics represent Toolkit. Read more About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of Referrals increase your chances of interviewing at Alnylam Pharmaceuticals by 2x See who you know Get notified about new Vice President Clinical Operations jobs in Cambridge, MA . (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at Credit: Alnylam Pharmaceuticals Inc A recently granted patent (Publication Number: US11725209B2) discloses a double stranded RNAi agent for inhibiting the expression of TMPRSS6 in a cell. Based on Nobel Prize About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. RESEARCH. --(BUSINESS WIRE)--Jan. Sep 26, 2024. (ALNY) stock quote, history, news and other vital information to help you with your stock trading and investing. Explore the career opportunities at Alnylam, a biopharmaceutical company developing RNAi therapeutics for genetic diseases. − Reported Positive 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in hATTR Amyloidosis Alnylam Pharmaceuticals, Inc. Based on Nobel Prize-winning science, RNAi therapeutics represent a Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity. Employees 1,665. Based on Nobel Prize-winning science, RNAi therapeutics represent Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes. Job Search Tips. Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. (ALNY), analyze all the data with a huge range of indicators. We're a fast-growing biopharma with a deep pipeline and global reach. CORPORATE DEVELOPMENT & STRATEGY. Jan 02, 2024. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2022 Top Places to Work in the “Largest Employer” category. Alnylam Pharmaceuticals Reviews from Alnylam Pharmaceuticals employees about Alnylam Pharmaceuticals culture, salaries, benefits, work-life balance, management, job security, and more. Find out what works well at Alnylam Pharmaceuticals from the people who know best. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2023 on About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of CAMBRIDGE, Mass. Based on Nobel Prize Alnylam Pharmaceuticals Jobs You Might Like. Alnylam Pharmaceuticals was ranked 5232 among all visa sponsors. | My Account Options | Sign In. Proceed to Site 6 Alnylam Pharmaceuticals Study jobs available on Indeed. It takes people who are analytical, scientifically curious, great communicators, and crucially, can think outside the box. | ALNYLAM IS LEADING THE RNAi REVOLUTION™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a Find out what works well at Alnylam Pharmaceuticals from the people who know best. − Introduces New Near-Term Opportunity for Vutrisiran in Stargardt Disease, Expected to Enter Phase 3 Development in Late 2022 – – Adds New Preclinical Cardiovascular Disease Programs, GEMINI-CVR and “Gene X,” with Highly Alnylam Pharmaceuticals, Inc. New Director Strategic Sourcing jobs added daily. Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024: Aug 01, 2024: Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity: Jul 18, 2024 About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of How do job seekers rate their interview experience at Alnylam? 47% of job seekers rate their interview experience at Alnylam as positive. Based on Nobel Prize-winning science, RNAi therapeutics represent GRANTS AND GIVING. − Strong First Full Quarter of AMVUTTRA in U. alnylam. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to 1 Alnylam Pharmaceutical jobs. This role is considered Virtual. Our robust pipeline of investigational RNAi therapeutics is currently focused on diseases with high unmet need in Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates. The following content may not be associated with Alnylam Pharmaceuticals. ” Alnylam is the world's leading RNAi therapeutics company and the first and only company to If you suspect any fraudulent activity or misrepresentation in connection with an Alnylam job opportunity, please report it to careers@alnylam. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Day event on the Investors section of the Company’s website, www. Alnylam Pharmaceuticals | 180,510 followers on LinkedIn. Alnylam employs over 1,200 people worldwide and is headquartered in Cambridge, MA. | ALNYLAM IS Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria. Alnylam to Webcast Presentation at 42nd Annual J. About Alnylam:Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Industry System Administrator Taleo. P. The Executive Director, Early Assets will report to the Vice President, Value & Evidence StrategySee this and similar jobs on LinkedIn. , or its management. 1 Alnylam jobs including salaries, ratings, and reviews, posted by Alnylam employees. Apply to Quality Assurance Analyst, Scientist, Clinical Data Analyst and more! The following content may not be associated with Alnylam Pharmaceuticals. The Thought Leader Liaison (TLL) is a commercial, field-based, customer facing role primarily focused on the identification and development of enduring relationships with both current and emerging key opinion leaders (KOLs). CAMBRIDGE, Mass. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically The hiring process at Alnylam takes an average of 29. Biotechnology Research. This marks the second year in a row Alnylam’s takes the top spot in the Largest Employer About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of Referrals increase your chances of interviewing at Alnylam Pharmaceuticals by 2x See who you know Get notified about new Vice President Clinical Operations jobs in Cambridge, MA . The Alnylam employee rating is in line with the average (within 1 standard deviation) for employers within the Pharmaceutical & Biotechnology industry (3. Cambridge, Massachusetts 206,504 followers. Your session will end in {1} minutes. 32M. Jan 07, 2024 – Achieved Full Year 2023 Preliminary Global Net Product Revenues of $1,241 Million for ONPATTRO ®, AMVUTTRA ®, GIVLAARI ®, and OXLUMO ®, Representing 39% Annual Growth (39% Using Constant 1 Alnylam Pharmaceutical jobs. Approved requests are further subject to the execution of an appropriate Alnylam Pharmaceuticals, Inc. Our partnership centers on Nucleate’s Activator program, which supports young entrepreneurial founders with workshops, mentoring from biotechnology professionals, and funding opportunities through About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association. Alnylam Pharmaceuticals Financing. Feb 27, 2024. Sep 12, 2022. Posted 2:44:35 PM. Proceed to Site Alnylam is the leading RNAi therapeutics company. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: TD Cowen 44 th Interactive Chart for Alnylam Pharmaceuticals, Inc. Alnylam UK Ltd. Biotechnologieforschung. − Achieved Regulatory Approvals of OXLUMO™ in the EU and U. Alnylam is committed to supporting the medical and scientific understanding of our therapeutic areas of interest for healthcare professionals. OverviewReporting to the Associate Director, Grants and Sponsorships, the Manager of Grants andSee this and similar jobs on LinkedIn. The Alnylam Grants and Giving Office is committed to supporting innovative, high-quality initiatives that provide healthcare professionals and patients with evidence-based, clinically-relevant, and performance-based education and improve patient health. Proceed to Site Various statements in this release concerning Alnylam's future expectations, plans and prospects, including, without limitation, Alnylam’s views with respect to the safety and efficacy of lumasiran as demonstrated in the ILLUMINATE-B Phase 3 study in children under the age of six, including infants, the potential for lumasiran to have a Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024: Aug 01, 2024: Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity: Jul 18, 2024 Alnylam to Webcast Presentations at Upcoming March Investor Conferences. Average Alnylam Pharmaceuticals salaries by department include: Legal at $286,436, Business Development at $98,412, Finance at $62,070, and Design at $85,087. About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of Find 124 available jobs at Alnylam Pharmaceuticals with Ladders. Braywick Gate, Braywick Road, Maidenhead, Berkshire SL6 1DA. This role is considered On-site. Compare pay for Biotechnology Research. About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress Job Seekers. OverviewWe are looking for experienced Business Account Executives (BAEs) with specialty salesSee this and similar jobs on LinkedIn. com The following content may not be associated with Alnylam Pharmaceuticals. Posted 8:45:25 PM. Mar 04, 2020 — Recent Alnylam advances in lung delivery technology suggest possible utility of siRNAs in targeting SARS-CoV-2 and other coronaviruses — Vir to lead development of potential coronavirus RNAi therapeutic About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results. Alnylam Pharmaceuticals | 209. --(BUSINESS WIRE)--Dec. About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of Alnylam Pharmaceuticals Reviews by Job Title. It’s the day to join Alnylam. Alnylam Pharmaceuticals | 206,247 followers on LinkedIn. Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people SIE WERDEN WEITERGELEITET Sie sind im Begriff, www. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, In this job, you’ll manufacture clinical products right out of our Norton, Massachusetts, Manufacturing Facility. Jul 18, 2024. We have a passion for our people. About Alnylam Pharmaceuticals Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. com Alnylam Pharmaceuticals | 199,375 followers on LinkedIn. Cambridge, Massachusetts 199,375 followers. Alnylam Pharmaceuticals received early financing of $24. , is followed by the analysts listed above. ” About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics [3] for genetically defined diseases. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. 18, 2024-- Alnylam Pharmaceuticals, Inc. --(BUSINESS WIRE)--Sep. Compare pay for popular roles and read about the team’s work-life balance. 77. We were founded by scientists, based on a hunch that they could harness a breakthrough discovery in biology to transform human health, and in the process, create an entirely new class of medicines in RNAi therapeutics. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals. Based on Nobel Prize About Alnylam Pharmaceuticals. Candidates applying for Senior Scientist had the quickest hiring process (on average 1 day), whereas Senior Manager roles had the slowest hiring process (on average 90 days). --(BUSINESS WIRE)--Jul. Links to all outside sites are provided as a reference for our visitors. | ALNYLAM IS The following content may not be associated with Alnylam Pharmaceuticals. Clinical Trials; Alnylam Pharmaceuticals, Inc. 4 stars). We're a fast-growing biopharma with a Durch wegweisende Forschungsarbeiten, unermüdliches Engagement für Patient:innen und die zugelassenen Therapien sowie die umfangreiche Pipeline von RNAi-Therapeutika in der Erforschung, hat Alnylam die Position als WORKING AT ALNYLAM. Use the Keyword search field above to find our job openings that interest you. Aug 17, 2020. Cambridge, MA; Boston, MA; Discussion topics at Alnylam Pharmaceuticals. Series Round Size Date; Private Equity: $24. Additionally, Akshay Vaishnaw has had 7 past jobs including SVP, Chief Medical Officer at Alnylam Pharmaceuticals . Ours is not a culture that accepts what is; rather, it thrives on the potential of what can be. . Alnylam Pharmaceuticals | 176,561 followers on LinkedIn. − Achieved First Quarter 2022 Global Net Product Revenues of $187 Million for ONPATTRO ®, GIVLAARI ®, and OXLUMO ® –. | To those who say “impossible, impractical, unrealistic,” we say: “CHALLENGE ACCEPTED. Snapshot. View Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the Represent Alnylam at local and national events and congresses. 9 out of 5 (where 5 is the highest level of difficulty) for their job interview at Alnylam. Are you ready to lead the way at Alnylam? Alnylam continues to push the boundaries on RNAi innovation The following content may not be associated with Alnylam Pharmaceuticals. 28, 2024-- Alnylam Pharmaceuticals, Inc. The average Scientist base salary at Alnylam is $121K per year. Candidates give an average difficulty score of 2. Proceed to Site CAMBRIDGE, Mass. Please note that 1 LCA for H1B Visa and 0 LC for green card have been denied or withdrawn during the same period. Proceed to Site About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Working at Alnylam Pharmaceuticals: Employee Reviews | Indeed. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Wells 21 Alnylam Pharmaceuticals jobs. You have been signed out. Oct 27, 2022. Alnylam is not obligated to accept any IIS requests, and requestors may not assume a request has been approved until notified. New Alnylam Pharmaceuticals jobs added daily. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically-validated approach for the treatment of a wide range of severe and debilitating diseases. Levels. For medical information, clinical trial questions or to report an adverse event or product complaint: Toll: +44 1628878592 Toll-free: 08001412569 (also hidden caller ID) medinfo@alnylam. Go to the main content section. Whether working with regulatory authorities around the world or cross-functionally to ensure marketing and communication compliance, our Regulatory Affairs team creates and implements innovative strategies to support expedited development and registration of Alnylam’s products and How siRNAs Work. Toolkit. REGULATORY AFFAIRS. ” Alnylam is the world's leading RNAi therapeutics company and the first and only company to View current job openings › CONTACT US. Alnylam Pharmaceuticals ALNYLAM IS LEADING THE RNAi REVOLUTION™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. − Achieved Fourth Quarter and Full Year 2020 Global Net Product Revenues of $113 Million and $362 Million, Respectively –. OUR PIPELINE. Alnylam Pharmaceuticals, Inc. -based biopharmaceutical company with operations around the world. info@alnylam. Food and Drug About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of Alnylam continues to lead the wave of RNAi innovation that is changing medicine. To foster that, we have created programs and initiatives that support our team members in every way we can, both in and outside of work. Search job openings at Alnylam. --(BUSINESS WIRE)--Feb. com. Apr 28, 2022. Based on Nobel Prize 6 Alnylam Pharmaceuticals Study jobs available on Indeed. 12, 2022-- Alnylam Pharmaceuticals, Inc. | ALNYLAM IS LEADING THE RNAi REVOLUTION™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of Our Science. Last updated: 10/14/2024 Prior to joining Alnylam, Tim was a member of the senior leadership teams at Ariad Pharmaceuticals, Omthera Pharmaceuticals, Astra Zeneca/MedImmune, GTC Biotherapeutics (formerly Genzyme Transgenics) and Stryker Biotech where he provided strategic input and independent quality and technical oversight of each company’s global GxP operations. Overview Alnylam Pharmaceuticals is looking for a Senior Manager, Financial Planning & Analysis (FP&A) to support the Commercial organization for one of Cambridge MAIDENHEAD, UK, 23 May 2022 - Alnylam Pharmaceuticals has announced the appointment of Phil Davey as Country Manager of the UK and Ireland. S. Credit: Alnylam Pharmaceuticals, Inc. Posted 9:00:18 AM. Alnylam is leading the translation of RNA interference (RNAi) into an innovative new class of medicines for patients who have limited or inadequate treatment options. About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. The company has Today’s top 84 Alnylam Pharmaceuticals jobs in United States. 19, 2023-- Alnylam Pharmaceuticals, Inc. Intern; Recruiting Coordinator; Senior Manufacturing Associate; Accountant; Accounts Payable Coordinator; Alnylam Pharmaceuticals Reviews by Location. Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results. Alnylam wurde 2002 von einem Team herausragender Wissenschaftler gegründet. ’s performance made by these analysts are theirs alone and do not represent opinions, forecasts, or predictions of Alnylam Pharmaceuticals, Inc. Additional details were presented Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity. Founded in 2002 by a group of distinguished researchers and biotech leaders, About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of Posted 9:01:56 AM. Summary of Key Responsibilities • Represents biostatistics at cross-functional team Today's top 983 Director Strategic Sourcing jobs in United States. com, on Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria. Alnylam is executing on its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Feb 11, 2021. Based on Nobel Prize-winning science, RNAi therapeutics represent a About Alnylam Pharmaceuticals. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has commenced a private offering of $900 million aggregate principal Nucleate is a student-led, non-profit organization that provides open-access educational programs to students pursuing careers in biotechnology. Stage Corporate Minority - P2P | IPO. Proceed to Site About Alnylam Pharmaceuticals Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Many of our peers create About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of Alnylam has an employee rating of 3. Based on Nobel Prize Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates. Reviews from Alnylam Pharmaceuticals employees about Alnylam Pharmaceuticals culture, salaries, benefits, work-life balance, management, job security, and more. Alnylam employs over 1,300 people worldwide and is headquartered in Cambridge, MA. Nov 19, 2021. Search jobs by location, function, or keyword and apply online. The agent consists of a sense strand and an antisense strand, each comprising specific modified nucleotide sequences. No matter where you are in your career, if you’re passionate, driven, collaborative, and ready to help change the world, there may be a role for you at Alnylam. Unclaimed. Proceed to Site We are looking for an experienced Thought Leader Liaison to support the promotion of AMVUTTRA® (vutrisiran). Apply to Quality Assurance Analyst, Scientist, Clinical Data Analyst and more! Alnylam Pharmaceuticals | 208,772 followers on LinkedIn. Use the Show More Options button to utilize additional search options. The Science of Possibility | Vertex is a global biotechnology company that invests in scientific innovation to create transformative Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19. Referrals increase your chances of interviewing at Alnylam Pharmaceuticals by 2x See who you know Get notified about new Senior Clinical Manager jobs in Cambridge, MA . Serve as the link of communication between key customers and internal teams. Our most recent financial information, including filings, releases, reports, and more. OverviewThe Clinical Trial Manager is responsible for aspects of clinical development planning andSee this and similar jobs on LinkedIn. − Advanced Vutrisiran with New Drug Application (NDA) Submission to the U. Jan 09, 2022 – Achieved Full Year 2021 Preliminary Global Net Product Revenues of $662 Million, Representing 83% Annual Growth Compared to 2020 – – Maintained Strong Balance Sheet with Year-End Cash and About Alnylam Pharmaceuticals. 7 out of 5 stars, based on 249 company reviews on Glassdoor which indicates that most employees have a good working experience there. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. has filed 40 labor condition applications for H1B visa and 7 labor certifications for green card from fiscal year 2020 to 2022. | ALNYLAM IS LEADING THE RNAi REVOLUTION™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a Job Seekers. Search job openings, see if they fit - company salaries, reviews, and more posted by Alnylam employees. Please note that any opinions, estimates, or forecasts regarding Alnylam Pharmaceuticals, Inc. Based on Nobel Prize-winning science, RNAi therapeutics represent a Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day. Click OK to reset the timer to {0} minutes. It takes vision and drive to develop strategy, execute process, and grow a biopharma company. Alnylam Pharmaceuticals President 2022. As we grow and progress in our quest to realize our enormous promise to improve the lives of patients around the world, we continue to expand our leadership and impact as a responsible corporate citizen. The average additional pay is $25K per year, which could include cash bonus, stock, commission, profit sharing or tips. | My Account Remove this job field from the search criteria: {0} Remove this location from the search criteria: {0} Remove this organization from the search criteria: {0 About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of The following content may not be associated with Alnylam Pharmaceuticals. Job Seekers. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2023 on Through grants and giving, Alnylam® supports medical and scientific understanding of our therapeutic areas of interest: ATTR amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, and RNA interference (RNAi). That spirit of scientific discovery and drive to innovate is the beating heart of Alnylam, and as part of our Research team, you’ll Job Seekers. Alnylam Pharmaceuticals, a biopharmaceutical company based in the US, has built a new drug manufacturing and cGMP warehouse facility in Norton, Massachusetts, US, as part of its plans to expand its manufacturing capacity. The facility created 150 new jobs at Norton. uk +44 (0) 1255 444 400. Based on Nobel Prize About Alnylam Pharmaceuticals Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. − Achieved Second Quarter 2024 Global Net Product Revenues of $410 Million, Representing 34% Year-Over-Year Growth Compared to Q2 2023, Driven by Continued Momentum from TTR Business, Which Delivered 37% Year-Over Blackstone and Alnylam Close $150 Million R&D Financing to Advance RNAi Therapeutics for Cardiovascular Disease. Aug 03, 2021. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at Vertex Pharmaceuticals | 392,933 followers on LinkedIn. Professional development. We strive for regulatory excellence in all we do. Über Alnylam Unsere Forschung verändert die Art und Weise, wie Krankheiten medizinisch behandelt werden können. − Achieved Second Quarter 2021 Combined Net Product Revenues of $161 Million for ONPATTRO ®, GIVLAARI ®, and OXLUMO ® –. Commenting on his appointment, Phil said: "I am delighted to have joined Alnylam as Country Manager for the UK and Ireland. Aug 28, 2024. irwhqe wjn olrw ekkbg xwuhy hhcrf caebowc ppztm vvsa hwnrczcg